Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.
You may also be interested in...
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva
Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.
Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer
Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.